Sun Pharmaceutical Industries Ltd.

Equities

SUNPHARMA

INE044A01036

Pharmaceuticals

Market Closed - NSE India S.E. 08:02:01 2024-03-28 am EDT 5-day change 1st Jan Change
1,621 INR +1.02% Intraday chart for Sun Pharmaceutical Industries Ltd. +4.60% +28.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cosmo Pharmaceuticals Partner Gets Regulatory Approval for Acne Treatment in Australia MT
Sun Pharmaceutical's Acne Drug Gets Approval in Australia MT
Sun Pharmaceutical Industries Limited Announces Approval of Winlevi in Australia CI
Upbeat Global Markets, Strong GDP Send Indian Equities to Record Closing High on Friday MT
Tianjin Chase Sun Pharmaceutical's 2023 Profit Slides 15% on Weak Revenue MT
India pharma companies develop versions of Wegovy to get in on weight-loss windfall RE
Gains in Banks, Financial Stocks Lift Indian Equities to End Higher on Tuesday; Nifty Hits Intraday Record High MT
Sun Pharmaceutical Industries to Buy Minority Stake in Surgimatix MT
Sun Pharmaceutical Industries Limited agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million. CI
Pfizer agrees to pay $93 million to settle Lipitor antitrust lawsuit RE
Indian Equities Close Higher Midweek, Led by Banking, IT Stocks MT
Indian drugmaker Lupin beats quarterly profit estimates on strong demand RE
Sun Pharmaceutical Industries Forms Unit for Business Expansion in UAE MT
Lupin Gets US FDA Nod for Bromfenac Ophthalmic Solution MT
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand RE
Sun Pharmaceutical Industries Forms New Subsidiary in US MT
Indian Equities Fall on Monday on Fading Hopes of Early US Rate Cut, Drop in Financial Stocks MT
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales RE
India's Jubilant Pharmova posts quarterly profit RE
Jefferies Adjusts Sun Pharmaceutical Industries’ Price Target to INR1,585 From INR1,535, Keeps at Buy MT
Sun Pharmaceutical Posts Rise in Fiscal Q3 Consolidated Net Profit MT
Transcript : Sun Pharmaceutical Industries Limited, Q3 2024 Earnings Call, Jan 31, 2024
Indian Equities Rebound Midweek Ahead of Interim Budget, US Fed Decision MT
India's Sun Pharma beats Q3 profit view on strong US sales RE
Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024 CI
Chart Sun Pharmaceutical Industries Ltd.
More charts
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows: - generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment; - other (6%) : primarily active pharmaceutical ingredients. At the end of March 2021, the group had 44 production plants worldwide. Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
37
Last Close Price
1,621 INR
Average target price
1,544 INR
Spread / Average Target
-4.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Sun Pharmaceutical Industries Ltd. - NSE India S.E.
  4. News Sun Pharmaceutical Industries Ltd.
  5. Sun Pharmaceutical Industries : Arm to Acquire Stake in Australian Bioproducts Company